Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005788 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00005788 is a Phase 2 study that was terminated before completion, run by Northwestern University.
The verdict
NCT00005788, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-04 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005788
The ClinicalTrials.gov registry entry for NCT00005788 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00005788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005788 about?
NCT00005788 is a clinical study titled "Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
What is the current status of trial NCT00005788?
This trial is currently terminated. It is a Phase 2 study. The study started on 1997-04. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00005788?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005788?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.